Home Medical Devices global-non-small-cell-lung-cancer-diagnostics-market

Medical Devices

Image

Global Non-Small Cell Lung Cancer Diagnostics Market – Industry Trends and Forecast to 2028

  • Medical Devices
  • Published Report
  • Aug 2021
  • Global
  • 350 Pages
  • No of Tables: 282
  • No of Figures: 52

Global Non-Small Cell Lung Cancer Diagnostics Market – Industry Trends and Forecast to 2028

Market Size in USD Billion

CAGR - % Diagram

Diagram Forecast Period 2020–2028
Diagram Market Size (Base Year) USD 1291.66 Million
Diagram Market Size (Forecast Year) USD 3463.37 Million
Diagram CAGR %

Global Non-Small Cell Lung Cancer Market, By Cancer Type (Lung Adenocarcinoma (LUAD), Lung Squamous Cell Carcinoma (LUSC), Large Cell Carcinoma And Others), Product (Reagents and Kits, Instruments, And Services And Softwares) Test(Imaging Test, Molecular Test, Biopsy, Sputum Cytology, Thoracentesis, Immunohistochemistry, And Others), End-User (Hospital, Clinical Laboratories, Academics And Others) Country (U.S., Mexico, Canada, France, Russia, Netherlands, U.K., Germany, Italy, Spain, Turkey, Belgium, Switzerland And Rest Of Europe, China, Thailand, Australia, Japan, South Korea, Singapore, Malaysia, Indonesia, Philippines, India, And Rest Of Asia-Pacific, South Africa Egypt, Saudi Arabia, UAE, Israel, And Rest Of Middle East And Africa, Brazil, Argentina Rest Of South America) Industry Trends And Forecast to 2028.

Market Analysis and Insights: Global Non-Small Cell Lung Cancer Diagnostics Market

The global non-small cell lung cancer diagnostics market is expected to reach USD 3,463.37 million by 2028 from USD 1,291.66 million in 2020, growing at a steady CAGR of 13.2% in the forecast period of 2021 to 2028.

Non-small cell lung cancer is a disease in which malignant cells or cancer cells are formed in the tissues of the lungs. These are of different types, and each type has different cancer cells that grow and spread in different ways. The non-small cell lung cancer (NSCLC) types are squamous cell carcinoma, large cell carcinoma, and adenocarcinoma. In squamous cell carcinoma, the cancer forms in the thin, flat cells lining inside the lungs and is called epidermoid carcinoma. Large cell carcinoma cancer begins in several types of large cells. The adenocarcinoma type of cancer begins in the cells that line the alveoli and make substances such as mucus. One of the significant risks for non-small cell lung cancer (NSCLC) is that smoking and symptoms include a cough that doesn't go away and shortness of breath. Various tests are used, such as imaging tests, molecular tests, biopsies, and others, to diagnose and examine the cancer stage. Diagnosis is essential to identify the disease in time so that proper treatment could be given to patients.

The factors driving the growth of the non-small cell lung cancer diagnostics market are the usage of artificial intelligence and machine learning to improve the diagnostics procedures coupled with the rise in a number of geriatric population that is more susceptible to non-small cell lung cancer. On the other hand, the high cost of instrumentation and challenges associated with brand equity might hamper the growth of the non-small cell lung cancer diagnostics market.

The rising healthcare expenditure in developing regions will create opportunities for the non-small cell lung cancer diagnostics market. However, the high competition among market players is acting as one of the challenges to the growth non-small cell lung cancer diagnostics market.

The non-small cell lung cancer diagnostics market report provides details of market share, new developments, and product pipeline analysis, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the non-small cell lung cancer diagnostics market scenario, contact Data Bridge Market Research for an Analyst Brief. Our team will help you create a revenue impact solution to achieve your desired goal.

Non-Small Cell Lung Cancer Diagnostics Market Global Non-Small Cell Lung Cancer Diagnostics Market Scope And Market Size

The global non-small cell lung cancer diagnostics market is segmented into four notable segments based on the cancer type, products, test, and end-user. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

  • On the basis of cancer type, the non-small cell lung cancer diagnostics market is segmented into lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), large cell carcinoma, and others. In 2021, the lung adenocarcinoma (LUAD) segment is expected to dominate the non-small cell lung cancer diagnostics market due to the growing cases of lung adenocarcinoma worldwide.
  • On the basis of products, the non-small cell lung cancer diagnostics market is segmented into reagents and kits, instruments and services, and software. In 2021, the instrument segment is expected to dominate the non-small cell lung cancer diagnostics market due to the rise in the usage of different instruments for diagnostic purposes in cancer.
  • On the basis of tests, the non-small cell lung cancer diagnostics market is a segmented imaging test, molecular test, biopsy, sputum cytology, thoracentesis, immunohistochemistry, and others. In 2021, the molecular test segment is expected to dominate the non-small cell lung cancer diagnostics market due to the growing molecular test for diagnostic purposes.
  • On the basis of end-users, the non-small cell lung cancer diagnostics market is segmented into hospitals, clinical laboratories, academics, and others. In 2021, the clinical laboratories segment is expected to dominate the non-small cell lung cancer diagnostics market due to the growing clinical research in cancer.

Non-Small Cell Lung Cancer Diagnostics Market Global Non-Small Cell Lung Cancer Diagnostics Market: Country Level Analysis

The global non-small cell lung cancer diagnostics market is segmented into four notable segments based on the cancer type, products, test, and end-user.

Countries covered in the global Non-small cell lung cancer diagnostics market report are the U.S., Mexico, Canada, France, Russia, Netherlands, U.K., Germany, Italy, Spain, Turkey, Belgium, Switzerland, and the rest of Europe, China, Thailand, Australia, Japan, South Korea, Singapore, Malaysia, Indonesia, Philippines, India, and rest of Asia-Pacific, South Africa Egypt, Saudi Arabia, UAE, Israel, and rest of the Middle East and Africa, Brazil, Argentina Rest of South America.

China, U.S., and Germany are dominating the global non-small cell lung cancer diagnostics market. The U.S. is expected to dominate the non-small cell lung cancer diagnostics market with the highest CAGR and highest market share due to growing cases of cancer. China is expected to dominate the non-small cell lung cancer diagnostics market due to the growing usage of artificial intelligence for diagnostic purposes. Germany is expected to dominate the non-small cell lung cancer diagnostics market due to the growing geriatric population that is more prone to developing lung cancer

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Asia-Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of sales channels are considered while providing forecast analysis of the country data.

Rising Demand For Diagnostic In The Medical Setting

The global non-small cell lung cancer diagnostics market also provides you with detailed market analysis for every country's growth in the industry with sales, components sales, the impact of technological development in IORT, and changes in regulatory scenarios with their support for the IORT market. The data is available for the historic period 2010 to 2019.

Competitive Landscape And Global Non-Small Cell Lung Cancer Diagnostics Market Share Analysis

Global non-small cell lung cancer diagnostics market competitive landscape provides details by a competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, India presence, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, and technology lifeline curve. The above data points provided are only related to the companies' focus related to the non-small cell lung cancer diagnostics market.

Some of the major players operating in the non-small cell lung cancer diagnostics market are Abbott Laboratories, F. Hoffmann-La Roche Ltd, Agilent Technologies, Inc., QIAGEN, Thermo Fisher Scientific Inc., Quest Diagnostics Incorporated, NeoGenomics Laboratories, Inc., NanoString, Janssen Pharmaceutical NV, Inivata Ltd, bioMérieux SA, Biotheranostics, OncoCyte Corporation Inc., GENERAL ELECTRIC COMPANY, Eckert & Ziegler, Dr. Lal PathLabs, RIVERAIN TECHNOLOGIES, PlexBio Co., Ltd, Oncimmune, Biodesix. among others.

The global non-small cell lung cancer diagnostics market is fragmented, and the major players have used various strategies such as collaborations, recognitions, agreements, and others, to increase their footprints in the non-small cell lung cancer diagnostics market.

For instance,

  • In March 2021, Agilent Technologies, Inc. acquired Resolution Bioscience for USD 550 million to strengthen its business in next-generation sequencing (NGS)-based oncology solutions.
  • In May 2021, QIAGEN launched FDA approved therascreen KRAS RGQ PCR Kit, which aids in the identification of non-small cell lung cancer (NSCLC) in patients
  • In June 2020, F. Hoffmann-La Roche Ltd launched an automated digital pathology algorithm, uPath PD-L1 (SP263) image analysis  , to diagnose non-small cell lung cancer (NSCLC) and improve the speed and accuracy of diagnosis treatment

SKU-

LIST OF TABLES 

TABLE 1 AGING WORLD POPULATION

TABLE 2 U.K. X RAY DEMAND 2018

TABLE 3 GLOBAL NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)

TABLE 4 GLOBAL LUNG ADENOCARCINOMA (LUAD) IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 5 GLOBAL LUNG SQUAMOUS CELL CARCINOMA (LUSC) IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 6 GLOBAL LARGE CELL CARCINOMA IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 7 GLOBAL OTHERS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 8 GLOBAL NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 9 GLOBAL INSTRUMENTS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 10 GLOBAL REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 11 GLOBAL REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 12 GLOBAL SERVICES AND SOFTWARES IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 13 GLOBAL NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 14 GLOBAL MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 15 GLOBAL MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 16 GLOBAL IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 17 GLOBAL IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 18 GLOBAL IMMUNOHISTOCHEMISTRY IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 19 GLOBAL BIOPSY IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2020

TABLE 20 GLOBAL SPUTUM CYTOLOGY IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 21 GLOBAL THORECENTESIS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 22 GLOBAL OTHERS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 23 GLOBAL NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 24 GLOBAL CLINICAL LABORATORIES IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 25 GLOBAL HOSPITAL IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 26 GLOBAL ACADEMICS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 27 GLOBAL INSTITUTES AND RESEARCH CENTERS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 28 GLOBAL NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 29 NORTH AMERICA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2019-2028 (USD MILLION)

TABLE 30 NORTH AMERICA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)

TABLE 31 NORTH AMERICA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 32 NORTH AMERICA REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 33 NORTH AMERICA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 34 NORTH AMERICA IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 35 NORTH AMERICA MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 36 NORTH AMERICA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 37 U.S. NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)

TABLE 38 U.S. NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 39 U.S. NON-SMALL REAGENTS AND KITS IN CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 40 U.S. NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 41 U.S. IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 42 U.S. MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 43 U.S. NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 44 CANADA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)

TABLE 45 CANADA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 46 CANADA REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 47 CANADA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 48 CANADA IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 49 CANADA MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 50 CANADA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 51 MEXICO NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)

TABLE 52 MEXICO NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 53 MEXICO REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 54 MEXICO NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 55 MEXICO IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 56 MEXICO MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 57 MEXICO NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 58 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2019-2028 (USD MILLION)

TABLE 59 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)

TABLE 60 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 61 ASIA-PACIFIC REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 62 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 63 ASIA-PACIFIC IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 64 ASIA-PACIFIC MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 65 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 66 CHINA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)

TABLE 67 CHINA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 68 CHINA REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 69 CHINA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 70 CHINA IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 71 CHINA MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 72 CHINA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 73 JAPAN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)

TABLE 74 JAPAN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 75 JAPAN REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 76 JAPAN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 77 JAPAN IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 78 JAPAN MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 79 JAPAN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 80 INDIA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)

TABLE 81 INDIA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 82 INDIA REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 83 INDIA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 84 INDIA IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 85 INDIA MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 86 INDIA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 87 SOUTH KOREA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)

TABLE 88 SOUTH KOREA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 89 SOUTH KOREA REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 90 SOUTH KOREA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 91 SOUTH KOREA IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 92 SOUTH KOREA MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 93 SOUTH KOREA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 94 AUSTRALIA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)

TABLE 95 AUSTRALIA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 96 AUSTRALIA REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 97 AUSTRALIA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 98 AUSTRALIA IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 99 AUSTRALIA MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 100 AUSTRALIA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 101 MALAYSIA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)

TABLE 102 MALAYSIA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 103 MALAYSIA REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 104 MALAYSIA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 105 MALAYSIA IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 106 MALAYSIA MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 107 MALAYSIA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 108 THAILAND NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)

TABLE 109 THAILAND NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 110 THAILAND REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 111 THAILAND NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 112 THAILAND IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 113 THAILAND MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 114 THAILAND NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 115 INDONESIA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)

TABLE 116 INDONESIA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 117 INDONESIA REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 118 INDONESIA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 119 INDONESIA IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 120 INDONESIA MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 121 INDONESIA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 122 SINGAPORE NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)

TABLE 123 SINGAPORE NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 124 SINGAPORE REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 125 SINGAPORE NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 126 SINGAPORE IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 127 SINGAPORE MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 128 SINGAPORE NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 129 PHILIPPINES NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)

TABLE 130 PHILIPPINES NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 131 PHILIPPINES REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 132 PHILIPPINES NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 133 PHILIPPINES IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 134 PHILIPPINES MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 135 PHILIPPINES NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 136 REST OF ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)

TABLE 137 EUROPE NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2019-2028 (USD MILLION)

TABLE 138 EUROPE NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)

TABLE 139 EUROPE NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 140 EUROPE REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 141 EUROPE NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 142 EUROPE IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 143 EUROPE MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 144 EUROPE NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 145 GERMANY NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)

TABLE 146 GERMANY NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 147 GERMANY REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 148 GERMANY NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 149 GERMANY IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 150 GERMANY MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 151 GERMANY NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 152 FRANCE NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)

TABLE 153 FRANCE NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 154 FRANCE REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 155 FRANCE NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 156 FRANCE IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 157 FRANCE MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 158 FRANCE NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 159 ITALY NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)

TABLE 160 ITALY NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 161 ITALY REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 162 ITALY NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 163 ITALY IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 164 ITALY MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 165 ITALY NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 166 RUSSIA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)

TABLE 167 RUSSIA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 168 RUSSIA REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 169 RUSSIA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 170 RUSSIA IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 171 RUSSIA MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 172 RUSSIA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 173 U.K. NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)

TABLE 174 U.K. NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 175 U.K. REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 176 U.K. NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 177 U.K. IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 178 U.K. MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 179 U.K. NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 180 SPAIN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)

TABLE 181 SPAIN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 182 SPAIN REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 183 SPAIN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 184 SPAIN IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 185 SPAIN MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 186 SPAIN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 187 TURKEY NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)

TABLE 188 TURKEY NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 189 TURKEY REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 190 TURKEY NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 191 TURKEY IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 192 TURKEY MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 193 TURKEY NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 194 SWITZERLAND NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)

TABLE 195 SWITZERLAND NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 196 SWITZERLAND REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 197 SWITZERLAND NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 198 SWITZERLAND IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 199 SWITZERLAND MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 200 SWITZERLAND NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 201 BELGIUM NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)

TABLE 202 BELGIUM NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 203 BELGIUM REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 204 BELGIUM NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 205 BELGIUM IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 206 BELGIUM MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 207 BELGIUM NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 208 NETHERLANDS NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)

TABLE 209 NETHERLANDS NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 210 NETHERLANDS REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 211 NETHERLANDS NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 212 NETHERLANDS IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 213 NETHERLANDS MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 214 NETHERLANDS NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 215 REST OF EUROPE NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)

TABLE 216 MIDDLE EAST AND AFRICA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2019-2028 (USD MILLION)

TABLE 217 MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)

TABLE 218 MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 219 MIDDLE EAST & AFRICA REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 220 MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 221 MIDDLE EAST & AFRICA IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 222 MIDDLE EAST & AFRICA MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 223 MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 224 SAUDI ARABIA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)

TABLE 225 SAUDI ARABIA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 226 SAUDI ARABIA REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 227 SAUDI ARABIA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 228 SAUDI ARABIA IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 229 SAUDI ARABIA MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 230 SAUDI ARABIA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 231 ISRAEL NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)

TABLE 232 ISRAEL NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 233 ISRAEL REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 234 ISRAEL NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 235 ISRAEL IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 236 ISRAEL MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 237 ISRAEL NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 238 SOUTH AFRICA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)

TABLE 239 SOUTH AFRICA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 240 SOUTH AFRICA REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 241 SOUTH AFRICA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 242 SOUTH AFRICA IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 243 SOUTH AFRICA MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 244 SOUTH AFRICA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 245 UAE NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)

TABLE 246 UAE NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 247 UAE REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 248 UAE NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 249 UAE IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 250 UAE MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 251 UAE NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 252 EGYPT NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)

TABLE 253 EGYPT NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 254 EGYPT REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 255 EGYPT NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 256 EGYPT IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 257 EGYPT MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 258 EGYPT NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 259 REST OF MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)

TABLE 260 SOUTH AMERICA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2019-2028 (USD MILLION)

TABLE 261 SOUTH AMERICA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)

TABLE 262 SOUTH AMERICA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 263 SOUTH AMERICA REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 264 SOUTH AMERICA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 265 SOUTH AMERICA IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 266 SOUTH AMERICA MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 267 SOUTH AMERICA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 268 BRAZIL NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)

TABLE 269 BRAZIL NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 270 BRAZIL REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 271 BRAZIL NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 272 BRAZIL IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 273 BRAZIL MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 274 BRAZIL NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 275 ARGENTINA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)

TABLE 276 ARGENTINA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 277 ARGENTINA REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 278 ARGENTINA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 279 ARGENTINA IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 280 ARGENTINA MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)

TABLE 281 ARGENTINA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 282 REST OF SOUTH AMERICA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

FREQUENTLY ASK QUESTIONS

Non-Small Cell Lung Cancer Diagnostics Market is growing at a steady CAGR of 13.2% by 2028.
Non-Small Cell Lung Cancer Diagnostics Market is expected to reach USD 3,463.37 million by 2028.
The major players operating in the non-small cell lung cancer diagnostics market are Abbott Laboratories, F. Hoffmann-La Roche Ltd, Agilent Technologies, Inc., QIAGEN, Thermo Fisher Scientific Inc., Quest Diagnostics Incorporated, NeoGenomics Laboratories, Inc., NanoString, Janssen Pharmaceutical NV, Inivata Ltd, bioMérieux SA, Biotheranostics, OncoCyte Corporation Inc., GENERAL ELECTRIC COMPANY, Eckert & Ziegler, Dr. Lal PathLabs, RIVERAIN TECHNOLOGIES, PlexBio Co., Ltd, Oncimmune, Biodesix. among others.
Germany is expected to dominate the non-small cell lung cancer diagnostics market due to the growing geriatric population that is more prone to developing lung cancer

BROWSE RELATED REPORTS

North America Non-Small Cell Lung Cancer Diagnostics Market – Industry Trends and Forecast to 2028
Europe Non-Small Cell Lung Cancer Diagnostics Market – Industry Trends and Forecast to 2028
Asia-Pacific Non-Small Cell Lung Cancer Diagnostics Market – Industry Trends and Forecast to 2028
Middle East And Africa Non-Small Cell Lung Cancer Diagnostics Market – Industry Trends and Forecast to 2028

BROWSE RELATED Blogs

Global Non-Small Cell Lung Cancer Diagnostics Market is Growing With a CAGR Of 13.2% in the Forecast Period of 2021 to 2028
North America Non-Small Cell Lung Cancer Diagnostics Market is Growing with a CAGR of 13.0% in the Forecast Period of 2021 to 2028

BROWSE RELATED Press Release

Increasing Private and Public Expenditure for the Development of Healthcare Infrastructure is driving the Growth of the Market
Abbott, F. Hoffmann-La Roche Ltd, Quest Diagnostics Incorporated are dominating the North America Non-Small Cell Lung Cancer Diagnostics Market in 2021
Free Sample Report

CHOOSE LICENCE TYPE

  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00

Can be used by entire organization across the globe + Downloadable and Printable PDF + 30 + Countries

Buy Now
Request for TOC Speak to Analyst Inquire Before Buying Free Sample Report
Advance Formative Research Customization Request for bulk Reports

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.

Banner

Client Testimonials

David Manning - Thermo Fisher Scientific
Director, Global Strategic Accounts,

Dear Ricky,
I want to thank you for the excellent market analysis (LIMS INSTALLED BASE DATA) that you and your team delivered, especially end of year on short notice. Sachin and Shraddha captured the requirements, determined their path forward and executed quickly.
You, Sachin and Shraddha have been a pleasure to work with – very responsive, professional and thorough. Your work is much appreciated.

Image
Manager - Market Analytics,
Uriah D. Avila - Zeus Polymer Solutions

Thank you for all the assistance and the level of detail in the market report. We are very pleased with the results and the customization. We would like to continue to do business.

Business Development Manager,
(Pharmaceuticals Partner for Nasal Sprays) | Renaissance Lakewood LLC

DBMR was attentive and engaged while discussing the Global Nasal Spray Market. They understood what we were looking for and was able to provide some examples from the report as requested. DBMR Service team has been responsive as needed. Depending on what my colleagues were looking for, I will recommend your services and would be happy to stay connected in case we can utilize your research in the future.

Image
Business Intelligence and Analytics,
Ipsen Biopharm Limited

We are impressed by the CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT report - so a BIG thanks to you colleagues.

Image
Competition Analyst,
Basler Web

I just wanted to share a quick note and let you know that you guys did a really good job. I’m glad I decided to work with you. I shall continue being associated with your company as long as we have market intelligence needs.

Image
Marketing Director,
Buhler Group

It was indeed a good experience, would definitely recommend and come back for future prospects.

COO,
A global leader providing Drug Delivery Services

DBMR did an outstanding job on the Global Drug Delivery project, We were extremely impressed by the simple but comprehensive presentation of the study and the quality of work done. This report really helped us to access untapped opportunities across the globe.

Image
Marketing Director,
Philips Healthcare

The study was customized to our targets and needs with well-defined milestones. We were impressed by the in-depth customization and inclusion of not only major but also minor players across the globe. The DBMR Market position grid helped us to analyze the market in different dimension which was very helpful for the team to get into the minute details.

Image
Product manager,
Fujifilms

Thankful to the team for the amazing coordination, and helping me at the last moment with my presentation. It was indeed a comprehensive report that gave us revenue impacting solution enabling us to plan the right move.

Image
Investor relations,
GE Healthcare

Thank you for the report, and addressing our needs in such short time. DBMR has outdone themselves in this project with such short timeframe.

Image
Market Analyst,
Medincell

We found the results of this study compelling and will help our organization validate a market we are considering to enter. Thank you for a job well done.

Image
Andrew - Senior Global Marketing Manager,
Medtronic (US)

I want to thank you for your help with this report – It’s been very helpful in our business planning and it well organized.

Image
Amarildo - Manager, Global Strategic Alignment
MasterCard

We believe the work done by Data Bridge Team for our requirements in the North America Loyalty Management Market was fantastic and would love to continue working with your team moving forward.

Image
Tor Hammer
Green Nexus LLc

Thank you for your quick response to this unfortunate circumstance. Please extend my thanks to your reach team. I will be contacting you in the future with further projects

Tommaso Finocchiaro
Market Intelligence Specialist Nippon Gasses

I acknowledge the difficulty given by the very short warning for this report, and I think that its quality and your delivering time have been very satisfying. Obviously, as a provider Data Bridge Market Research will be considered as a plus for future needs of Nippon Gases.

Yuki Kopyl (Asian Business Development Department)
UENO FOOD TECHNO INDUSTRY, LTD. (JAPAN)

Xylose report was very useful for our team. Thank you very much & hope to work with you again in the future